Business Context and Reporting Period
XORTX Therapeutics Inc. is a late clinical-stage biotechnology company incorporated in British Columbia, Canada, and listed on Nasdaq (XRTX) and the TSX Venture Exchange. The company focuses on developing therapies for diseases modulated by aberrant purine and uric acid metabolism, specifically targeting gout, autosomal dominant polycystic kidney disease (ADPKD), and acute kidney injury (AKI). This filing is an Annual Report on Form 20-F for the fiscal year ended December 31, 2024.
Key Financial Metrics
The company has no revenue from product sales and continues to incur significant losses as it advances its clinical programs.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3,313,346) | $(2,158,065) | $(7,718,882) |
| Cash and Cash Equivalents | $2,473,649 | $3,447,665 | $10,434,196 |
| Accumulated Deficit | $(21,168,253) | $(17,854,907) | $(15,696,842) |
| Total Assets | $4,094,527 | $5,467,964 | $N/A |
| Total Liabilities | $757,990 | $825,938 | $N/A |
Note: The 2022 net loss figure in the text ($7.7M) differs from the 2022 comprehensive loss in the table ($7.8M) due to currency translation differences.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 53% in 2024 compared to 2023, driven by higher investor relations expenses ($1.36M vs $0.92M) and professional fees, partially offset by a reduction in the fair value adjustment on derivative warrant liability ($1.04M gain in 2024 vs $3.64M gain in 2023).
- Cash Burn: Cash and cash equivalents decreased by approximately $974,000 during 2024, primarily due to operating losses and share issuance costs, despite raising approximately $3.5M in gross proceeds from equity offerings.
- Derivative Liability: The derivative warrant liability increased to $572,000 from $531,000 due to new warrant issuances in 2024, though the fair value adjustment provided a non-cash gain of $1.04M.
- Capital Structure: The company completed a registered direct offering and private placement in October 2024, raising approximately $1.5M, and a non-brokered offering in early 2024 raising approximately $2.0M.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Lead Program (XRx-026): The company is prioritizing XRx-026 for the treatment of gout (specifically for allopurinol-intolerant patients). Following FDA Type B meeting responses, the company plans to conduct a pharmacokinetic bridging study to support a New Drug Application (NDA) via the 505(b)(2) pathway.
- ADPKD Program (XRx-008): The company is preparing for a Phase 3 registration clinical trial for ADPKD. The FDA has indicated that a single clinical trial with a one-year treatment period could be sufficient for accelerated approval.
- Going Concern: The auditors have issued a "Going Concern" opinion, noting that recurring losses raise substantial doubt about the company's ability to continue as a going concern without additional financing.
Key Risks and Contingencies
- Capital Requirements: The company requires substantial additional funding to complete clinical trials and commercialization. Failure to secure financing could force delays or cessation of operations.
- Regulatory Approval: There is no guarantee that the FDA will approve XRx-026 or XRx-008. The 505(b)(2) pathway relies on prior FDA findings which could be challenged.
- Nasdaq Compliance: In April 2025, the company received notice of non-compliance with Nasdaq's minimum bid price requirement (shares trading below $1.00 for 30 consecutive days). The company has 180 days to regain compliance.
- Internal Controls: Management identified a material weakness in internal control over financial reporting related to the period-end closing process and management review controls.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance against the projected burn rate to determine the immediate need for capital raising.
- Nasdaq Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
- FDA Milestones: Track the initiation and results of the pharmacokinetic bridging study for XRx-026 and the timeline for the Phase 3 trial for XRx-008.
- Dilution Risk: Review the terms of outstanding warrants (including derivative liabilities) and options, noting the significant number of shares issuable upon exercise.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal controls over financial reporting.